Menu Search
Equities

Orion Oyj

ORNAV:HEX

Orion Oyj

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)45.25
  • Today's Change0.35 / 0.78%
  • Shares traded7.02k
  • 1 Year change+21.80%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Orion Oyj's revenues fell -11.26% from 1.34bn to 1.19bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 349.50m to 216.80m, a -37.97% decrease.
Gross margin59.89%
Net profit margin23.19%
Operating margin29.16%
Return on assets22.25%
Return on equity37.60%
Return on investment28.25%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Orion Oyj fell by 225.90m. However, the company earned 119.00m from its operations for a Cash Flow Margin of 10.00%. In addition the company used 108.40m on investing activities and also paid 243.20m in financing cash flows.
Cash flow per share2.78
Price/Cash flow per share16.29
Book value per share6.58
Tangible book value per share5.10
More ▼

Balance sheet in EURView more

Orion Oyj has a Debt to Total Capital ratio of 21.74%, a higher figure than the previous year's 21.04%.
Current ratio2.42
Quick ratio1.41
Total debt/total equity0.2778
Total debt/total capital0.2174
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)3.75%
Div growth rate (5 year)1.55%
Payout ratio (TTM)34.26%
EPS growth(5 years)1.94
EPS (TTM) vs
TTM 1 year ago		90.56
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.